Purdue Frederick

Purdue Frederick was the pharmaceutical company that developed OxyContin and became central to the book’s account of the opioid crisis: its commercial pivot from an established morphine product to a much broader market for oxycodone was followed by evidence of abuse, a federal criminal case, and a settlement that punished a holding company without preventing Purdue Pharma from continuing to sell OxyContin. Its history is also a story of corporate identity: the company that pleaded guilty was not the same corporate entity that remained in the market.

Origins and the move into pain relief

Purdue Frederick was a little-known, family-owned company based in Stamford, Connecticut, when three research psychiatrists and brothers—Mortimer, Raymond, and Arthur Sackler—bought it from its original Manhattan-based owners in 1952. It then had only a few employees and annual sales of $20,000. The new owners first built the business around over-the-counter products, including laxatives, earwax remover, and Betadine, the antiseptic used to wash down the Apollo 11 spacecraft after its mission to the moon.

The Sacklers expanded internationally in the 1970s, acquiring Scottish and British drug companies, and moved toward pain treatment with MS Contin in 1984. Derived from morphine, the end-of-life painkiller took its name from Contin, an abbreviation of continuous. By the mid-1990s, annual sales had reached $170 million, but the product’s patent was nearing expiration. Purdue Frederick developed OxyContin to fill the commercial gap, taking a reformulation of oxycodone beyond hospice and end-of-life care. Oxycodone itself had been developed in 1917 from thebaine, an ingredient in the Persian poppy.

The family behind the company was famously private and more widely known for philanthropy than drug development. The Sacklers’ cultural and philanthropic profile formed a striking counterpoint to the company’s expanding role in prescription pain relief. OxyContin’s development turned that business into a subject of urgent public scrutiny.

OxyContin and the evidence before approval

The U.S. Food and Drug Administration approved OxyContin in late 1995. Yet the application review signed by the agency’s top examiner, Curtis Wright, documented risks relevant to how the drug could be used. It stated that crushing the tablets could release the medication immediately rather than gradually, described withdrawal symptoms observed in several patients during clinical trials, and reported that 68 percent of the oxycodone could be recovered from one crushed pill, liquefied, and injected.

This information sat uneasily beside Purdue’s later claim that it had no knowledge of the drug’s abuse problems until February 2000. Wright’s approval summary urged caution in promotional materials, including a warning to limit competitive promotion. The book notes that Wright went on to work as a consultant for Purdue Pharma two years later; that sequence adds to questions about the boundary between regulatory oversight and industry, without by itself establishing why he made the earlier approval decisions.

In January 2002, Art Van Zee drove to Maryland to testify before a U.S. Food and Drug Administration advisory committee considering the agency’s oversight of narcotics. He challenged the company’s assurances in a meeting where Purdue executives and prominent pain-management experts were present, many of whom acknowledged that they were or had been paid speakers for Purdue. The forum ended with experts urging close monitoring of new drugs for abuse and addiction. For critics of Purdue Frederick’s marketing, the advice underscored how much depended on recognizing the risks after a drug had reached patients.

Investigation and negotiated plea

By 2006, the federal case against Purdue had become a contest over both the scope of the charges and the consequences for the company and its executives. Prosecutors had considered felony charges beyond misbranding, including mail fraud, wire fraud, and money laundering. The initial government proposal was a $1 billion fine; Purdue first offered $10 million. The eventual narrowing of charges and penalties reflected prolonged plea negotiations, but the book also describes lobbying and pressure from the company’s lawyers, including Rudy Giuliani.

In 2005, Purdue’s lawyers questioned the investigative tactics of John Brownlee, the U.S. attorney leading the Virginia case. Then–deputy attorney general James Comey raised concerns with Brownlee, who drove to Washington to explain his strategy. Comey told him to return to Virginia and continue the case. The pressure resurfaced in October 2006, on the night before the plea agreement was due to expire. At a Purdue lawyer’s request, a senior Justice Department official called Brownlee at home to seek an extension. Brownlee refused to keep negotiating under pressure; later that night, Purdue accepted the agreement rather than face the risk of more serious charges or a trial in western Virginia.

The case’s final terms were substantially narrower than the charges prosecutors had initially contemplated. Purdue Frederick, a Purdue-owned holding company, pleaded guilty to a felony misbranding charge. The company’s executives Paul Goldenheim, Michael Friedman, and Howard Udell pleaded guilty to misdemeanor misbranding charges. They did not stipulate to direct knowledge of the misbranding; the plea language instead allowed the court to accept the stated facts in support of their pleas. Brownlee’s name appeared on a list of U.S. attorneys facing dismissal eight days after Purdue accepted the deal, although he was not ultimately fired. The episode drew criticism of Attorney General Alberto Gonzales and renewed attention to efforts to influence the work of U.S. attorneys’ offices.

Settlement, penalties, and corporate distinction

In May 2007, Brownlee announced the settlement in a downtown Roanoke office building. Purdue agreed to pay $600 million to resolve federal criminal and civil misbranding charges. It admitted that for six years it had marketed OxyContin fraudulently as less prone to abuse and as having fewer narcotic side effects than immediate-release versions. Its executives were assessed $34.5 million in connection with their misdemeanor pleas, paid by the firm on their behalf. The combined penalties were about 90 percent of the company’s profits from OxyContin between its 1996 launch and 2001, when Purdue dropped the language about the timed-release mechanism’s ability to reduce abuse liability. The fine was described as the eleventh-largest paid by a pharmaceutical firm in the history of the United States Department of Justice.

The total fine of $634.5 million was divided among law-enforcement agencies and state and federal Medicaid programs, including reimbursement for claims arising from the misbranding. The settlement also funded Virginia’s Prescription Monitoring Program and resolved $130 million in civil claims. The Lee County sheriff’s office received placebo OxyContin pills for use in drug stings. The settlement planned an Abingdon sentencing hearing where grieving parents could address the executives in court. Under the plea agreement, the executives would not serve jail time, though the judge retained responsibility for approving the terms of probation and community service.

A critical distinction shaped the practical effect of the punishment. During its five-year probation, Purdue Frederick was barred from participating in federal health programs including Medicaid, Medicare, and Tricare. Purdue Pharma itself was not the entity excluded and remained permitted to participate in those programs—and to continue selling OxyContin. The executives were also barred from doing business with federal health programs and repeatedly appealed that decision, without success. The book presents the separation between the pleading entity and the continuing seller as a central limitation of the corporate penalty: the guilty plea and fine were real, but the company structure left the drug’s market presence intact.

A wider accountability problem

The account places Purdue Frederick’s case within a broader landscape of industry influence and incomplete oversight. Investigative reporting later revealed that drug-industry-funded meetings between regulators and pharmaceutical executives had taken place at expensive hotels at least annually since 2002. The resulting practice of enriched enrollment allowed companies to exclude study participants who did not respond well to a drug, potentially tilting the evidence presented for approval. Separately, reporting on the American Pain Society and the American Academy of Pain Medicine found that the organizations advocated wider opioid use for long-term chronic pain while receiving millions from companies that made the drugs. A Senate investigation examined the American Pain Foundation, Purdue, and other organizations and companies, but its results remained sealed in the Senate Finance Committee’s office.

The company’s significance in the book therefore extends beyond the amount paid or the wording of its plea. The narrative follows families whose shame initially kept them from speaking publicly, and it shows how people seeking help encountered gaps between health care and criminal justice. It does not reduce those institutional failures to Purdue Frederick alone. Instead, the company’s trajectory—from a small seller of household products to the maker of a widely marketed painkiller, then to a guilty holding company whose related seller remained in business—offers a concrete case of how corporate accountability could fall short of stopping the commercial activity at the center of the controversy.